Bicalutamide With or Without Everolimus in Treating Patients With Recurrent or Metastatic Prostate Cancer
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such
as bicalutamide, may lessen the amount of androgens made by the body. Everolimus may stop the
growth of tumor cells by blocking some of the enzymes needed for cell growth.
PURPOSE: This phase II trial is studying bicalutamide and everolimus to see how well they
work compared with bicalutamide in treating patients with recurrent or metastatic prostate
cancer.